Literature DB >> 7544687

In vitro evaluation of Pyrularia thionin-anti-CD5 immunotoxin.

S E Gasanov1, E D Rael, N E Gasanov, L P Vernon.   

Abstract

The membrane-active peptide, Pyrularia thionin, purified from Pyrularia pubera, was covalently conjugated to an anti-CD5 monoclonal antibody. The membrane-active properties of thionin were not affected by the conjugation. The immunotoxin killed CD5+ lymphocytes in vitro at a concentration of 0.1 nmol/10(7) cells after 2 h of incubation. The immunotoxin also inhibited the proliferation of T cells in vitro, stimulated either by mitogens or in the mixed lymphocyte reaction. It was shown by electron paramagnetic resonance of spin probes and differential scanning calorimetry that the ability of the immunotoxin to perturb the lipid phase of membranes is close to that of unconjugated thionin. The results obtained suggest that Pyrularia-thionin-anti-CD5 conjugate may be useful for graft-versus-host disease therapy and potentially in the treatment of CD5+ leukemia and lymphomas.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7544687     DOI: 10.1007/bf01527408

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  27 in total

1.  Internalization and intracellular fate of anti-CD5 monoclonal antibody and anti-CD5 ricin A-chain immunotoxin in human leukemic T cells.

Authors:  S Ravel; M Colombatti; P Casellas
Journal:  Blood       Date:  1992-03-15       Impact factor: 22.113

2.  Amantadine potentiates T lymphocyte killing by an anti-pan-T cell (CD5) ricin A-chain immunotoxin.

Authors:  S Siena; S Villa; M Bregni; G Bonnadonna; A M Gianni
Journal:  Blood       Date:  1987-01       Impact factor: 22.113

3.  [Interaction of cobra venom cytotoxin with oriented phospholipid multi-bilayers].

Authors:  T F Aripov; S E Gasanov; B A Salakhutdinov; A S Sadykov
Journal:  Dokl Akad Nauk SSSR       Date:  1986

4.  Evaluation of ricin A-chain immunotoxins directed against human T cells.

Authors:  O W Press; E S Vitetta; A G Farr; J A Hansen; P J Martin
Journal:  Cell Immunol       Date:  1986-10-01       Impact factor: 4.868

5.  Evaluation of antihuman T lymphocyte saporin immunotoxins potentially useful in human transplantation.

Authors:  S Siena; M Bregni; A Formosa; D Martineau; D A Lappi; G Bonadonna; A M Gianni
Journal:  Transplantation       Date:  1988-11       Impact factor: 4.939

6.  In vitro and in vivo properties of an anti-CD5-momordin immunotoxin on normal and neoplastic T lymphocytes.

Authors:  G Porro; A Bolognesi; P Caretto; G Gromo; P Lento; G Mistza; T Sciumbata; F Stirpe; D Modena
Journal:  Cancer Immunol Immunother       Date:  1993-05       Impact factor: 6.968

7.  [Intermembrane exchange of lipids induced by cobra venom cytotoxins].

Authors:  S E Gasanov; T F Aripov; B A Salakhutdinov
Journal:  Biofizika       Date:  1990 Nov-Dec

Review 8.  Immunotoxin therapy for cancer.

Authors:  L H Pai; I Pastan
Journal:  JAMA       Date:  1993-01-06       Impact factor: 157.335

9.  Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma.

Authors:  R J Kreitman; P Bailon; V K Chaudhary; D J FitzGerald; I Pastan
Journal:  Blood       Date:  1994-01-15       Impact factor: 25.476

10.  Antitumor activity of the single-chain immunotoxin BR96 sFv-PE40 against established breast and lung tumor xenografts.

Authors:  P N Friedman; D F Chace; P A Trail; C B Siegall
Journal:  J Immunol       Date:  1993-04-01       Impact factor: 5.426

View more
  2 in total

1.  Snake Venom Cytotoxins, Phospholipase A2s, and Zn2+-dependent Metalloproteinases: Mechanisms of Action and Pharmacological Relevance.

Authors:  Sardar E Gasanov; Ruben K Dagda; Eppie D Rael
Journal:  J Clin Toxicol       Date:  2014-01-25

Review 2.  The expansion of targetable biomarkers for CAR T cell therapy.

Authors:  Michelle H Townsend; Gajendra Shrestha; Richard A Robison; Kim L O'Neill
Journal:  J Exp Clin Cancer Res       Date:  2018-07-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.